Revance Therapeutics Inc. (RVNC) Receives Average Recommendation of “Buy” from Analysts
Revance Therapeutics Inc. (NASDAQ:RVNC) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are covering the stock. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $38.53.
RVNC has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a research note on Wednesday, October 5th. Brean Capital reissued a “hold” rating on shares of Revance Therapeutics in a research note on Thursday, June 23rd.
Revance Therapeutics (NASDAQ:RVNC) traded down 1.38% on Monday, hitting $14.30. 55,517 shares of the stock were exchanged. The company has a 50 day moving average of $15.36 and a 200 day moving average of $16.08. Revance Therapeutics has a one year low of $12.54 and a one year high of $42.41. The stock’s market capitalization is $407.32 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/revance-therapeutics-inc-rvnc-receives-average-recommendation-of-buy-from-analysts.html
Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.86) by $0.02. The business had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.06 million. Revance Therapeutics had a negative return on equity of 40.44% and a negative net margin of 28,586.33%. Revance Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. On average, equities research analysts forecast that Revance Therapeutics will post ($3.53) earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the stock. ProShare Advisors LLC increased its stake in shares of Revance Therapeutics by 2.9% in the second quarter. ProShare Advisors LLC now owns 23,688 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 670 shares during the last quarter. American International Group Inc. boosted its position in Revance Therapeutics by 10.9% in the second quarter. American International Group Inc. now owns 11,769 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 1,161 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Revance Therapeutics by 2.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 66,263 shares of the biopharmaceutical company’s stock valued at $902,000 after buying an additional 1,320 shares during the period. BlackRock Advisors LLC boosted its position in Revance Therapeutics by 15.8% in the second quarter. BlackRock Advisors LLC now owns 9,802 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 1,338 shares during the period. Finally, Teachers Advisors Inc. boosted its position in Revance Therapeutics by 7.8% in the second quarter. Teachers Advisors Inc. now owns 32,072 shares of the biopharmaceutical company’s stock valued at $436,000 after buying an additional 2,322 shares during the period.
About Revance Therapeutics
Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.